Lite Strategy, Inc. (LITS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lite Strategy, Inc. (LITS) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($112.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LITS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Lite Strategy, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Lite Strategy, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lite Strategy, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lite Strategy, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baird Medical Investment Holdings Limited
NASDAQ:BDMD
|
-0.090x |
|
Dynamic Precision Industry
TWO:8928
|
-0.251x |
|
K Way Information
TWO:5201
|
-0.031x |
|
Sentronic International
TWO:3232
|
0.055x |
|
Daewon Co. Ltd
KQ:007680
|
0.059x |
|
Studio Mir Co. Ltd.
KQ:408900
|
-0.078x |
|
Tirta Mahakam Resources Tbk
JK:TIRT
|
0.003x |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
0.163x |
Annual Cash Flow Conversion Efficiency for Lite Strategy, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Lite Strategy, Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see LITS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $16.93 Million | $-20.84 Million | -1.231x | +19.46% |
| 2024-06-30 | $33.02 Million | $-50.47 Million | -1.529x | +28.28% |
| 2023-06-30 | $24.62 Million | $-52.48 Million | -2.131x | -129.18% |
| 2022-06-30 | $52.41 Million | $-48.75 Million | -0.930x | -43.93% |
| 2021-06-30 | $49.47 Million | $-31.96 Million | -0.646x | -- |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.